Emergent BioSolutions | EBS - Gross Profit On Sales


Emergent BioSolutions reported $10M in Gross Profit on Sales for its fiscal quarter ending in March of 2023.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 257.76M 778K Dec/2025
Akebia Therapeutics USD 49.21M 13.25M Mar/2025
ALKERMES USD 338.34M 72.51M Dec/2025
Alnylam Pharmaceuticals USD 829.31M 219.56M Dec/2025
Amarin USD 22.21M 28.15M Sep/2025
ANI Pharmaceuticals USD 124.18M 12.39M Dec/2025
BioMarin Pharmaceutical USD 713.01M 81.81M Dec/2025
Coherus Biosciences USD 4.95M 15.34M Mar/2025
Exact Sciences USD 583.93M 21.48M Sep/2025
Exelixis USD 572.18M 7M Dec/2025
Glaxosmithkline GBP 8.75B 2.92B Sep/2025
Heron Therapeutics USD 23.35M 1.6M Sep/2024
Ionis Pharmaceuticals USD 195M 40M Dec/2025
Ironwood Pharmaceuticals USD 85.24M 44.1M Jun/2025
Lexicon Pharmaceuticals USD -16.16M 2.89M Jun/2024
Lonza CHF 1.29B 248M Jun/2025
Merck USD 13.42B 431M Sep/2025
Moderna USD 226M 583M Dec/2025
Myriad Genetics USD 143.8M 8M Sep/2025
Nektar Therapeutics USD 13.75M 650K Jun/2024
Neurocrine Biosciences USD 787.9M 7M Dec/2025
Pacira USD 142.25M 11.34M Dec/2025
Pfizer USD 3.54B 7.61B Sep/2025
PTC Therapeutics USD 148.38M 39.31M Dec/2025
Sanofi EUR 8.45B 1.31B Dec/2025
Sarepta Therapeutics USD 43.55M 204.36M Dec/2025
United Therapeutics USD 315.5M 286.6M Dec/2025
Vanda Pharmaceuticals USD 50.6M 5.5M Dec/2024
Xoma 992K 846K Jun/2024